These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 19441912)

  • 1. Preclinical compounds for the treatment of overactive bladder.
    Giannitsas K; Konstantinopoulos A; Patsialas C; Athanasopoulos A; Perimenis P
    Expert Opin Ther Pat; 2009 Feb; 19(2):107-17. PubMed ID: 19441912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimuscarinics and overactive bladder: other mechanism of action.
    Yamaguchi O
    Neurourol Urodyn; 2010; 29(1):112-5. PubMed ID: 19693952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in the pharmacotherapy of the overactive bladder.
    Sellers DJ; McKay N
    Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
    Saks EK; Arya LA
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of adherence to drug therapy in patients with overactive bladder.
    Basra RK; Wagg A; Chapple C; Cardozo L; Castro-Diaz D; Pons ME; Kirby M; Milsom I; Vierhout M; Van Kerrebroeck P; Kelleher C
    BJU Int; 2008 Sep; 102(7):774-9. PubMed ID: 18616691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
    Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A
    Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open to debate. The Motion: antimuscarinics are the mainstay of therapy for overactive bladder.
    Chapple C; Cruz F
    Eur Urol; 2008 Jul; 54(1):226-30. PubMed ID: 18439750
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy.
    Dobrek Ł; Juszczak K; Wyczółkowski M; Thor PJ
    Acta Pol Pharm; 2011; 68(6):807-21. PubMed ID: 22125944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent advances in the development of antimuscarinic agents for overactive bladder.
    Smith AL; Wein AJ
    Trends Pharmacol Sci; 2010 Oct; 31(10):470-5. PubMed ID: 20801529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of fesoterodine.
    Vella M; Cardozo L
    Expert Opin Drug Saf; 2011 Sep; 10(5):805-8. PubMed ID: 21639817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder.
    Harpe SE; Szeinbach SL; Caswell RJ; Corey R; McAuley JW
    J Urol; 2007 Dec; 178(6):2532-6; discussion 2536. PubMed ID: 17937937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better management of patients with overactive bladder with antimuscarinics?
    MacDiarmid S
    Int J Clin Pract; 2008 Jan; 62(1):3-4. PubMed ID: 18173809
    [No Abstract]   [Full Text] [Related]  

  • 19. Changing treatments for overactive bladder.
    Waine E; Stott M
    Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
    Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
    Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.